Gamida Cell Analyst Ratings
Gamida Cell Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/15/2023 | 368.75% | Needham | → $6 | Reiterates | Buy → Buy |
06/30/2023 | 368.75% | Needham | → $6 | Reiterates | Buy → Buy |
05/22/2023 | 759.37% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
05/19/2023 | 368.75% | JMP Securities | $8 → $6 | Maintains | Market Outperform |
05/16/2023 | 368.75% | Oppenheimer | $8 → $6 | Maintains | Outperform |
05/16/2023 | 368.75% | Needham | → $6 | Reiterates | Buy → Buy |
04/20/2023 | 368.75% | Needham | $8 → $6 | Maintains | Buy |
04/19/2023 | 759.37% | HC Wainwright & Co. | $5 → $11 | Maintains | Buy |
04/18/2023 | 290.62% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
04/17/2023 | 525% | JMP Securities | → $8 | Maintains | Market Perform |
03/28/2023 | 368.75% | JMP Securities | → $6 | Maintains | Market Outperform |
03/28/2023 | 290.62% | HC Wainwright & Co. | $22 → $5 | Maintains | Buy |
03/28/2023 | 525% | Oppenheimer | $10 → $8 | Maintains | Outperform |
11/22/2022 | 1071.87% | JMP Securities | → $15 | Maintains | Market Outperform |
11/22/2022 | 525% | Needham | $9 → $8 | Maintains | Buy |
11/15/2022 | 681.25% | Oppenheimer | $15 → $10 | Maintains | Outperform |
11/04/2022 | 1071.87% | JMP Securities | → $15 | Maintains | Market Outperform |
09/29/2022 | 603.12% | Needham | $12 → $9 | Maintains | Buy |
09/19/2022 | 1228.12% | JMP Securities | → $17 | Maintains | Market Outperform |
08/15/2022 | 1228.12% | JMP Securities | → $17 | Maintains | Market Outperform |
08/01/2022 | 1228.12% | JMP Securities | → $17 | Maintains | Market Outperform |
06/01/2022 | 1228.12% | JMP Securities | → $17 | Maintains | Market Outperform |
11/16/2021 | 837.5% | Needham | $14 → $12 | Maintains | Buy |
11/16/2021 | 1071.87% | Oppenheimer | $17 → $15 | Maintains | Outperform |
03/09/2021 | 993.75% | Needham | $17 → $14 | Maintains | Buy |
07/01/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
05/26/2020 | 915.62% | Piper Sandler | → $13 | Initiates Coverage On | → Overweight |
05/21/2020 | 1228.12% | Needham | $19 → $17 | Maintains | Buy |
04/27/2020 | 1071.87% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
02/26/2020 | 1228.12% | BMO Capital | $19 → $17 | Maintains | Outperform |
09/20/2019 | 1150% | JMP Securities | → $16 | Initiates Coverage On | → Market Outperform |
11/20/2018 | 1462.5% | RBC Capital | → $20 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/15/2023 | 368.75% | 尼德姆 | → 6 美元 | 重申 | 购买 → 购买 |
06/30/2023 | 368.75% | 尼德姆 | → 6 美元 | 重申 | 购买 → 购买 |
05/22/2023 | 759.37% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
05/19/2023 | 368.75% | JMP 证券 | 8 美元 → 6 美元 | 维护 | 市场表现跑赢大盘 |
05/16/2023 | 368.75% | 奥本海默 | 8 美元 → 6 美元 | 维护 | 跑赢大盘 |
05/16/2023 | 368.75% | 尼德姆 | → 6 美元 | 重申 | 购买 → 购买 |
04/20/2023 | 368.75% | 尼德姆 | 8 美元 → 6 美元 | 维护 | 购买 |
04/19/2023 | 759.37% | HC Wainwright & Co. | 5 美元 → 11 美元 | 维护 | 购买 |
04/18/2023 | 290.62% | HC Wainwright & Co. | → 5 美元 | 重申 | → 购买 |
04/17/2023 | 525% | JMP 证券 | → 8 美元 | 维护 | 市场表现 |
03/28/2023 | 368.75% | JMP 证券 | → 6 美元 | 维护 | 市场表现跑赢大盘 |
03/28/2023 | 290.62% | HC Wainwright & Co. | 22 美元 → 5 美元 | 维护 | 购买 |
03/28/2023 | 525% | 奥本海默 | 10 美元 → 8 美元 | 维护 | 跑赢大盘 |
11/22/2022 | 1071.87% | JMP 证券 | → 15 美元 | 维护 | 市场表现跑赢大盘 |
11/22/2022 | 525% | 尼德姆 | 9 美元 → 8 美元 | 维护 | 购买 |
11/15/2022 | 681.25% | 奥本海默 | 15 美元 → 10 美元 | 维护 | 跑赢大盘 |
2022 年 4 月 11 日 | 1071.87% | JMP 证券 | → 15 美元 | 维护 | 市场表现跑赢大盘 |
2022 年 9 月 29 日 | 603.12% | 尼德姆 | 12 美元 → 9 美元 | 维护 | 购买 |
09/19/2022 | 1228.12% | JMP 证券 | → 17 美元 | 维护 | 市场表现跑赢大盘 |
08/15/2022 | 1228.12% | JMP 证券 | → 17 美元 | 维护 | 市场表现跑赢大盘 |
08/01/2022 | 1228.12% | JMP 证券 | → 17 美元 | 维护 | 市场表现跑赢大盘 |
2022 年 1 月 6 日 | 1228.12% | JMP 证券 | → 17 美元 | 维护 | 市场表现跑赢大盘 |
11/16/2021 | 837.5% | 尼德姆 | 14 美元 → 12 美元 | 维护 | 购买 |
11/16/2021 | 1071.87% | 奥本海默 | 17 美元 → 15 美元 | 维护 | 跑赢大盘 |
2021 年 9 月 3 日 | 993.75% | 尼德姆 | 17 美元 → 14 美元 | 维护 | 购买 |
2020 年 1 月 7 日 | — | Evercore ISI 集团 | 启动覆盖开启 | → 跑赢大盘 | |
05/26/2020 | 915.62% | 派珀·桑德勒 | → 13 美元 | 启动覆盖开启 | → 超重 |
05/21/2020 | 1228.12% | 尼德姆 | 19 美元 → 17 美元 | 维护 | 购买 |
2020 年 4 月 27 日 | 1071.87% | HC Wainwright & Co. | → 15 美元 | 启动覆盖开启 | → 购买 |
02/26/2020 | 1228.12% | BMO Capital | 19 美元 → 17 美元 | 维护 | 跑赢大盘 |
09/20/2019 | 1150% | JMP 证券 | → 16 美元 | 启动覆盖开启 | → 市场跑赢大盘 |
11/20/2018 | 1462.5% | 加拿大皇家银行资本 | → 20 美元 | 启动覆盖开启 | → 跑赢大盘 |
What is the target price for Gamida Cell (GMDA)?
Gamida Cell(GMDA)的目标价格是多少?
The latest price target for Gamida Cell (NASDAQ: GMDA) was reported by Needham on August 15, 2023. The analyst firm set a price target for $6.00 expecting GMDA to rise to within 12 months (a possible 368.75% upside). 19 analyst firms have reported ratings in the last year.
Needham于2023年8月15日公布了Gamida Cell(纳斯达克股票代码:GMDA)的最新目标股价。这家分析公司将目标股价定为6.00美元,预计GMDA将在12个月内升至6.00美元(可能上涨368.75%)。去年有19家分析公司公布了评级。
What is the most recent analyst rating for Gamida Cell (GMDA)?
分析师对Gamida Cell(GMDA)的最新评级是多少?
The latest analyst rating for Gamida Cell (NASDAQ: GMDA) was provided by Needham, and Gamida Cell reiterated their buy rating.
Gamida Cell(纳斯达克股票代码:GMDA)的最新分析师评级由Needham提供,Gamida Cell重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Gamida Cell (GMDA)?
Gamida Cell(GMDA)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gamida Cell, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gamida Cell was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究(包括浏览公开财务报表、与Gamida Cell的高管和客户交谈以及听取财报电话会议)后得出股票评级。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Gamida Cell的最后一次评级是在2023年8月15日提交的,因此您应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Gamida Cell (GMDA) correct?
分析师对 Gamida Cell (GMDA) 的评级是否正确?
While ratings are subjective and will change, the latest Gamida Cell (GMDA) rating was a reiterated with a price target of $0.00 to $6.00. The current price Gamida Cell (GMDA) is trading at is $1.28, which is within the analyst's predicted range.
虽然评级是主观的,会发生变化,但最新的Gamida Cell(GMDA)评级得到了重申,目标股价为0.00美元至6.00美元。Gamida Cell(GMDA)目前的交易价格为1.28美元,在分析师的预测区间内。